Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2021—The FDA authorized the first COVID-19 direct-to-consumer test system—LabCorp’s Pixel COVID-19 Test Home Collection Kit, for use by any person 18 years and older without a prescription.
January 2021—TechLab has partnered with New River Valley COVID-19 Task Force to expand future COVID-19 testing capacity. Under the agreement, the New River Health District, headquartered in Christianburg, Va., secures access to TechLab’s analyte-specific reagents for SARS-CoV-2 for $7 to $9 per use.
January 2021—The Food and Drug Administration approved the next -generation sequencing–based FoundationOne CDx test (Foundation Medicine) as a companion diagnostic to identify fusions in neurotrophic receptor tyrosine kinase genes NTRK1, NTRK2, and NTRK3 in DNA isolated from tumor tissue specimens from patients with solid tumors eligible for treatment with larotrectinib (Vitrakvi, Bayer Healthcare Pharmaceuticals).
January 2021—Bio-Rad Laboratories launched its SARS-CoV-2, Flu, RSV positive and negative run controls. The products enable laboratories to evaluate day-to-day and lot-to-lot variation of their multiplexed molecular assay and test for operator proficiency.
December 2020—Protein-based, ready-to-use liquid Matrix Plus Cholesterol Reference kits are available from Verichem Laboratories. The kits are designed to support overall system quality control and CLIA compliance and are for the calibration or calibration verification of cholesterol and uric acid wet assays on clinical testing systems. The materials contain esterified and free cholesterol from bovine serum. The standard kit with the sixth level F covers 12 concentration points; cholesterol concentrations range from 40 to 750 mg/dL and uric acid concentrations from 2 to 30 mg/dL. Active components are verified using standard reference materials from the National Institute of Standards and Technology. Shelf life is 21 months from the date of manufacture. Ready-to-use, liquid Total Protein and Albumin reference materials are also available. The combined Total Protein/Albumin Standard kit, along with the optional standalone Total Protein/Albumin Standard level F, are designed for the calibration and calibration verification of albumin and total protein assays on a wide number of clinical testing systems. The standards are prepared with human serum albumin and gamma-globulin serum proteins in a saline-based solution. Shelf life is 24 months from the manufacturing date.
December 2020—Roche announced FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic rearranged during transfection fusion–positive non-small cell lung cancer as detected by an FDA-approved test. Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations.
December 2020—The FDA approved Gilead Sciences’ antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization. Veklury should be administered only in a hospital or health care setting capable of providing acute care comparable to inpatient hospital care. Veklury is the first treatment for COVID-19 to receive FDA approval.
December 2020—ARUP Laboratories announced the availability of a combined test to detect and differentiate COVID-19, influenza, and/or respiratory syncytial virus in individuals with respiratory symptoms consistent with COVID-19. The test can be performed on specimens collected using a deep nasal swab or on specimens collected from the back of the throat and the front of both nostrils.
December 2020—Siemens Healthineers announced a master collaboration agreement with Novartis Pharma to design, develop, and commercialize diagnostic tests for therapeutic products across Novartis’ therapeutic pipeline. The initial program will focus on developing a serum neurofilament light chain immunoassay for patients with multiple sclerosis and other neurological diseases.
December 2020—Thermo Fisher Scientific introduced a service designed to enable its team of technical experts to monitor Wi-Fi-connected Thermo Scientific TSX series ultra-low temperature freezers.
